Crispr Therapeutics AG

Developing cures for serious human genetic diseases

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

Website

TOP 100 Scale-ups

Being among the TOP 100 Startups in Switzerland has become a seal of approval for founders, and the TOP 100 Swiss Startup Ranking provides them with the recognition they deserve. As startups cannot appear in the startup ranking for more than five years after incorporation, the TOP 100 Swiss Scale-up Ranking has been introduced. A growth jury is asked to select the TOP 100 Swiss Scale-ups. These companies, aged five up to 10 years, show the greatest potential for further growth and represent the future Swiss unicorns

Website

Crispr Therapeutics AG

Developing cures for serious human genetic diseases

Headquarter:
Zug

Foundation Date:
October 2013

Technology:

  • Biotech

Sectors:

  • Biotech

Support received

  • Support TOP 100